Use of cytomegalovirus antigenemia as a marker for preemptive treatment.
Guirado
L
L
Renal Transplantation Unit, Puigvert Foundation, Barcelona, Spain.
Herreros
M A
MA
Muñoz
J M
JM
Rabella
N
N
Facundo
C
C
Agraz
I
I
Díaz
M
M
Diaz
J M
JM
Durán
F
F
Solà
R
R
D000284:Administration, Oral; D000328:Adult; D000956:Antigens, Viral / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007275:Injections, Intravenous; D016030:Kidney Transplantation / Q000276:immunology*; D010750:Phosphoproteins / Q000097:blood; D011183:Postoperative Complications / Q000821:virology*; D014763:Viral Matrix Proteins / Q000097:blood
D000956:Antigens, Viral; D015415:Biomarkers; D007166:Immunosuppressive Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir